Search

Your search keyword '"Stoltefuss, Andrea"' showing total 14 results
Start Over Author "Stoltefuss, Andrea"
14 results on '"Stoltefuss, Andrea"'

1. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma

Author

Habringer, Stefan, Demel, Uta M., Fietz, Anne-Katrin, Lammer, Felicitas, Schroers, Roland, Hofer, Silvia, Bairey, Osnat, Braess, Jan, Meier-Stiegen, Anna Sofia, Stuhlmann, Reingard, Schmidt-Hieber, Martin, Hoffmann, Johannes, Zinngrebe, Bettina, Kaiser, Ulrich, Reimer, Peter, Möhle, Robert, Fix, Peter, Höffkes, Heinz-Gert, Langenkamp, Ulrich, Büschenfelde, Christian Meyer zum, Hopfer, Olaf, Stoltefuß, Andrea, La Rosée, Paul, Blasberg, Henning, Jordan, Karin, Kaun, Stephan, Meurer, Anna, Unteroberdörster, Meike, von Brünneck, Ann-Christin, Capper, David, Heppner, Frank L., Chapuy, Björn, Janz, Martin, Schwartz, Stefan, Konietschke, Frank, Vajkoczy, Peter, Korfel, Agnieszka, and Keller, Ulrich

Published
2024
Full Text
View/download PDF

2. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.

Author

Kutsch, Nadine, Giza, Adam, Robrecht, Sandra, Stumpf, Janina, Federhen, Anno, Stoltefuß, Andrea, Vehling‐Kaiser, Ursula, Koenigsmann, Michael, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Illmer, Thomas, Schlag, Rudolf, Dörfel, Steffen, Gaska, Tobias, Kiehl, Michael, Müller‐Hagen, Sigrun, Moorahrend, Enno, Linde, Hartmut, and Schlenska‐Lange, Anke

Subjects
CHRONIC lymphocytic leukemia, CYCLOPHOSPHAMIDE, FLUDARABINE, RITUXIMAB, OVERALL survival
Abstract

Long‐term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long‐term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first‐line treatment with FCR were analyzed, of which 293 (70.3%) were treated outside of clinical trials. The median observation time from first‐line was 95.8 (interquartile range 58.7–126.8) months. Focusing on data of 194 (46.5%) patients who received FCR first‐line treatment after 2013 (start of data collection within GCLLSG registry), responses were documented in 85% of the patients, non‐responses in 15%, and for 3.6% the assessment was missing. Median event‐free survival (EFS, time until disease progression, subsequent treatment, or death) was 60.2 months with a 5‐year EFS‐rate of 50.6%. Patients with higher‐risk disease, characterized by unmutated IGHV (N = 78), had a median EFS of 45.4 months with a 5‐year EFS rate of 36.3%, while the median EFS was 77.5 months with a 5‐year EFS rate of 60.3% in patients with mutated IGHV (N = 40). Median overall survival was not reached with a 5‐year survival rate of 92.7%. In summary, first‐line FCR was associated with long EFS, especially in patients exhibiting a mutated IGHV status. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma

Author

Habringer, Stefan, primary, Demel, Uta M., additional, Fietz, Anne-Katrin, additional, Lammer, Felicitas, additional, Schroers, Roland, additional, Hofer, Silvia, additional, Bairey, Osnat, additional, Braess, Jan, additional, Meier-Stiegen, Anna Sofia, additional, Stuhlmann, Reingard, additional, Schmidt-Hieber, Martin, additional, Hoffmann, Johannes, additional, Zinngrebe, Bettina, additional, Kaiser, Ulrich, additional, Reimer, Peter, additional, Möhle, Robert, additional, Fix, Peter, additional, Höffkes, Heinz-Gert, additional, Langenkamp, Ulrich, additional, Büschenfelde, Christian Meyer zum, additional, Hopfer, Olaf, additional, Stoltefuß, Andrea, additional, La Rosée, Paul, additional, Blasberg, Henning, additional, Jordan, Karin, additional, Kaun, Stephan, additional, Meurer, Anna, additional, Unteroberdörster, Meike, additional, von Brünneck, Ann-Christin, additional, Capper, David, additional, Heppner, Frank L., additional, Chapuy, Björn, additional, Janz, Martin, additional, Schwartz, Stefan, additional, Konietschke, Frank, additional, Vajkoczy, Peter, additional, Korfel, Agnieszka, additional, and Keller, Ulrich, additional

Published
2023
Full Text
View/download PDF

4. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation

Author

Bittrich, Max, primary, Kriegsmann, Katharina, additional, Tietze-Stolley, Carola, additional, Movassaghi, Kamram, additional, Grube, Matthias, additional, Vucinic, Vladan, additional, Wehler, Daniela, additional, Burchert, Andreas, additional, Schmidt-Hieber, Martin, additional, Rank, Andreas, additional, Dürk, Heinz A., additional, Metzner, Bernd, additional, Kimmich, Christoph, additional, Hentrich, Marcus, additional, Kunz, Christian, additional, Hartmann, Frank, additional, Khandanpour, Cyrus, additional, de Wit, Maike, additional, Holtick, Udo, additional, Kiehl, Michael, additional, Stoltefuß, Andrea, additional, Kiani, Alexander, additional, Naumann, Ralph, additional, Scholz, Christian W., additional, Tischler, Hans-Joachim, additional, Görner, Martin, additional, Brand, Franziska, additional, Ehmer, Martin, additional, and Kröger, Nicolaus, additional

Published
2023
Full Text
View/download PDF

5. P1122: A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA

Author

Habringer, Stefan, primary, Demel, Uta, additional, Fietz, Anne-Katrin, additional, Lammer, Felicitas, additional, Schroers, Roland, additional, Hofer, Silvia, additional, Bairey, Osnat, additional, Braess, Jan, additional, Sofia Meier-Stiegen, Anna, additional, Stuhlmann, Reingard, additional, Schmidt-Hieber, Martin, additional, Hoffmann, Johannes, additional, Zinngrebe, Bettina, additional, Kaiser, Ulrich, additional, Reimer, Peter, additional, Möhle, Robert, additional, Fix, Peter, additional, Höffkes, Heinz-Gert, additional, Langenkamp, Ulrich, additional, Büschenfelde, Christian Meyer Zum, additional, Hopfer, Olaf, additional, Stoltefuß, Andrea, additional, La Rosée, Paul, additional, Blasberg, Henning, additional, Jordan, Karin, additional, Kaun, Stephan, additional, Unteroberdörster, Meike, additional, von Brünneck, Ann-Christin, additional, Capper, David, additional, Heppner, Frank L., additional, Chapuy, Björn, additional, Janz, Martin, additional, Schwartz, Stefan, additional, Konietschke, Frank, additional, Vajkoczy, Peter, additional, Korfel, Agnieszka, additional, and Keller, Ulrich, additional

Published
2023
Full Text
View/download PDF

6. General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia

Author

Gökbuget, Nicola, primary, Ihrig, Kristina, additional, Stadler, Michael, additional, Stelljes, Matthias, additional, Elmaagli, Ahmed, additional, Starck, Michael, additional, Raffel, Simon, additional, Stoltefuss, Andrea, additional, Viardot, Andreas, additional, Kreuzer, Karl-Anton, additional, Heidenreich, Daniela, additional, Renzelmann, Andrea, additional, Wäsch, Ralph, additional, Topp, Max S., additional, Ritter, Barbara, additional, Reimer, Peter, additional, Beck, Joachim, additional, Westermann, Jörg, additional, Wendelin, Knut, additional, Alakel, Nael, additional, Hanoun, Maher, additional, Serve, Hubert, additional, and Hoelzer, Dieter, additional

Published
2023
Full Text
View/download PDF

7. Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Author

Kriegsmann, Katharina, primary, Bittrich, Max, additional, Sauer, Sandra, additional, Tietze-Stolley, Carola, additional, Movassaghi, Kamran, additional, Grube, Matthias, additional, Vucinic, Vladan, additional, Wehler, Daniela, additional, Burchert, Andreas, additional, Schmidt-Hieber, Martin, additional, Rank, Andreas, additional, Dürk, Heinz A., additional, Metzner, Bernd, additional, Kimmich, Christoph, additional, Hentrich, Marcus, additional, Kunz, Christian, additional, Hartmann, Frank, additional, Khandanpour, Cyrus, additional, de Wit, Maike, additional, Holtick, Udo, additional, Kiehl, Michael, additional, Stoltefuß, Andrea, additional, Kiani, Alexander, additional, Naumann, Ralph, additional, Scholz, Christian W., additional, Tischler, Hans-Joachim, additional, Görner, Martin, additional, Brand, Franziska, additional, Ehmer, Martin, additional, and Kröger, Nicolaus, additional

Published
2023
Full Text
View/download PDF

8. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Author

Goekbuget, Nicola, primary, Viardot, Andreas, additional, Steffen, Björn, additional, Hahn, Joachim, additional, Spriewald, Bernd, additional, Martin, Sonja, additional, Raffel, Simon, additional, Teichmann, Lino L., additional, Trummer, Arne, additional, Alsdorf, Winfried, additional, Morgner, Anke, additional, Schwartz, Stefan, additional, Stelljes, Matthias, additional, Vucinic, Vladan, additional, Alakel, Nael, additional, Stoltefuß, Andrea, additional, Baldus, Claudia D., additional, Brüggemann, Monika, additional, Serve, Hubert, additional, and Hoelzer, Dieter, additional

Published
2022
Full Text
View/download PDF

9. Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Author

Burchert, Andreas, primary, Saussele, Susanne, additional, Michel, Christian, additional, Metzelder, Stephan K, additional, Hochhaus, Andreas, additional, Gattermann, Norbert, additional, Crysandt, Martina, additional, Schafhausen, Philippe, additional, Bormann, Matthias, additional, Radsak, Markus P., additional, Guerci-Bresler, Agnès, additional, Illmer, Thomas, additional, Goebeler, Maria E, additional, Herhaus, Peter, additional, Teichmann, Lino L., additional, Franke, Georg-Nikolaus, additional, Lang, Fabian, additional, Krause, Stefan W., additional, Möhle, Robert, additional, Klausmann, Martine, additional, Stegelmann, Frank, additional, Lutz, Christoph, additional, Etienne, Gabriel, additional, Stoltefuß, Andrea, additional, Göthert, Joachim R, additional, Ernst, Thomas, additional, Neubauer, Andreas, additional, Hehlmann, Rüdiger, additional, Aminossadati, Behnaz, additional, Wittenberg, Michael, additional, Pfirrmann, Markus, additional, Schade-Brittinger, Carmen, additional, le Coutre, Philipp, additional, and Nicolini, Franck E., additional

Published
2022
Full Text
View/download PDF

10. Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry

Author

Kutsch, Nadine, primary, Fink, Anna Maria, additional, Federhen, Anno, additional, Giza, Adam, additional, Robrecht, Sandra, additional, Stumpf, Janina, additional, Stoltefuß, Andrea, additional, Vehling-Kaiser, Ursula, additional, Koenigsmann, Michael, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Stilgenbauer, Stephan, additional, Illmer, Thomas, additional, Schlag, Rudolf, additional, Dörfel, Steffen, additional, Gaska, Tobias, additional, Kiehl, Michael G., additional, Fischer, Kirsten, additional, Eichhorst, Barbara, additional, and Hallek, Michael, additional

Published
2022
Full Text
View/download PDF

11. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Author

Goekbuget, Nicola, Viardot, Andreas, Steffen, Björn, Hahn, Joachim, Spriewald, Bernd, Martin, Sonja, Raffel, Simon, Teichmann, Lino L., Trummer, Arne, Alsdorf, Winfried, Morgner, Anke, Schwartz, Stefan, Stelljes, Matthias, Vucinic, Vladan, Alakel, Nael, Stoltefuß, Andrea, Baldus, Claudia D., Brüggemann, Monika, Serve, Hubert, and Hoelzer, Dieter

Published
2022
Full Text
View/download PDF

12. Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

Author

Goekbuget, Nicola, primary, Stoltefuß, Andrea, additional, Topp, Max, additional, Schwartz, Stefan, additional, Renzelmann, Andrea, additional, Faul, Christoph, additional, Hertenstein, Bernd, additional, Vucinic, Vladan, additional, Wachsmuth, Maria, additional, Wilke, Anne C, additional, Baumann, Lena, additional, Tichy, Diana, additional, Brüggemann, Monika, additional, and Viardot, Andreas, additional

Published
2021
Full Text
View/download PDF

13. MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Author

Furstenau, Moritz, Giza, Adam, Schneider, Christof, Tausch, Eugen, Robrecht, Sandra, Ritgen, Matthias, Bittenbring, Jörg, Hebart, Holger F., Schöttker, Björn, Illert, Anna Lena, Graeven, Ullrich, Stoltefuss, Andrea, Heinrich, Bernhard, Eckert, Robert, Fink, Anna-Maria, Stumpf, Janina, Simon, Florian, Fischer, Kirsten, Al-Sawaf, Othman, Langerbeins, Petra, Kleinert, Fanni, Weiss, Jonathan, Kreuzer, Karl-Anton, Schilhabel, Anke, Brüggemann, Monika, Eichhorst, Barbara F., Stilgenbauer, Stephan, Hallek, Michael, and Cramer, Paula

Abstract

Background

Published
2023
Full Text
View/download PDF

14. Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Author

Goekbuget, Nicola, Schwartz, Stefan, Faul, Christoph, Topp, Max S., Subklewe, Marion, Renzelmann, Andrea, Stoltefuss, Andrea, Hertenstein, Bernd, Wilke, Anne, Raffel, Simon, Jäkel, Nadja, Vucinic, Vladan, Niemann, Dirk Markus, Reiser, Lena, Serve, Hubert, Brüggemann, Monika, and Viardot, Andreas

Abstract

Older patients (pts) with newly diagnosed ALL are ineligible for unmodified pediatric-based therapies. Although results are improved with age-adapted, dose-reduced regimens including MRD-based treatment modification, there is much space for further improvement.Therefore, the GMALL study group developed a trial to evaluate Blinatumomab, a CD19 directed bi-specific T-cell engager, in sequence with chemotherapy in this patient population with high medical need (NCT 03480438). Importantly, Blinatumomab replaced three cycles of standard consolidation chemotherapy.Pts aged 56 - 76 years (yrs) with CD19-positive, Ph-neg B-precursor ALL wereeligible. The primary endpoint was complete hematologic remission (CR) afterinduction (1 cycle chemo, 1 cycle Blinatumomab) and the key secondary endpoint was molecular response (table 1). The efficacy population included pts treated with dose reduced and shortened induction I (IP1) and Blinatumomab 1 or early death (ED). Induction was followed by 3 further Blinatumomab cycles alternating with age adapted consolidation cycles (HDMTX/ASP, HDAC, reinduction and maintenance) according to GMALL protocols for older pts (Gökbuget et al, ASH 2021).

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results